-
-
The First Batch of 140,000 Pieces of Anti-Epidemic Materials Has Been Delivered! Stay Strong, Shanghai! We Are Here For You!
2022-03-15
(14 March 2022) As the epidemic situation in Shanghai escalates, Fosun Foundation, under the guidance of the Shanghai Civil Affairs Bureau, rapidly activated its wartime mechanism and launched its anti-epidemic action program.As of 23:00 on 14 March, Fosun Foundation has donated more than 140,000 pieces of anti-epidemic materials to various District Civil Affairs
-
-
A Special Gift to Support Hong Kong’s Anti-epidemic Efforts
2022-03-11
(11 March 2022) Since Fosun Foundation announced on 19 February the donation of HK$10 million anti-epidemic materials to Hong Kong, two batches of materials, including COVID-19 rapid antigen test kits, face masks, protective suits, isolation gowns, forehead thermometers, oximeters and other common anti-epidemic materials, have arrived in Hong Kong s
-
-
Fosun Foundation’s Second Batch of More Than 500,000 Pieces of Anti-epidemic Materials Arrives in Hong Kong Successively to Aid High-risk Groups and Grassroots Families
2022-03-10
Hong Kong, 10 March 2022 – In the face of the severe fifth wave of epidemic in Hong Kong, Fosun Foundation quickly launched the epidemic relief work of “Let’s Work Hand in Hand and Combat the Epidemic Together” in Hong Kong. After the first batch of 250,000 sets of COVID-19 rapid antigen test kits and 50,000 pieces of N95 respirators were donated to non-pro
-
-
St. John Opens Manhattan Boutique at New York City’s 655 Madison Avenue
2022-03-09
March 5, 2022 - American luxury fashion house, St. John, best known for women’s knitwear has announced a new 2,512 square foot boutique which opened in February 2022.Deputy CEO Andy Lew shared, “Manhattan is an important market for us. We’re proud to remain an integral part of the upper east side community for generations now. Madison Avenue draws New Yorkers and
-
-
Clarification statement on the fraudulent use of Fosun's name by Fosun Invest Global AB
2022-03-08
Recently, our company has become aware of a misappropriation of its name “Fosun” where fraudsters who have used the name of "Fosun" without our authorization in relation to alleged illegal sale of securities to investors under the name of "Fosun Invest Global AB".Our company isdeeply concerned about this matter and hereby makes the following clarification st
-
-
Targeted Anti-Epidemic Support, Fosun Foundation Delivers the First Batch of Anti-epidemic Materials to Grassroots Families in Hong Kong
2022-03-02
(2 March 2022, Hong Kong) “Let’s Work Hand in Hand and Combat the Epidemic Together”. In an effort to support Hong Kong’s fightagainst the COVID-19 epidemic, Fosun Foundation urgently deployed the first batch anti-epidemic materials including 250,000 sets of COVID-19 rapid antigen test kits and 50,000 pieces of N95 respirators to Hong Kong. The first batch
-
-
汉利康Ⓡ Approved by NMPA for New Indication Differentiated Strategy Benefits a Wider Patient Population
2022-03-01
汉利康Ⓡ Approved by NMPA for New IndicationDifferentiated Strategy Benefits a Wider Patient PopulationShanghai, China, March1st, 2022 – Shanghai Henlius Biotech, Inc. (2696. HK) today announced that 汉利康® (rituximab injection), its first independently developed monoclonal antibody, has been granted approval by the National Medical Products Administration (NMPA) in
-
-
Fosun Foundation’s First Batch of 250,000 Sets of COVID-19 Rapid Antigen Test Kits Arrives in Hong Kong
2022-02-25
Hong Kong, 25 February 2022 – In an effort to support Hong Kong’s fight against the severe fifth wave of COVID-19 epidemic, Fosun Foundation announced last week the donation of HK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and face masks to Hong Kong. The first batch of 250,000 sets of COVID-19 rapid antigen test kits arrived in Hong Kong from Shanghai this morning, and 50,000 pieces of N95 respirators are expected to be arrived in Hong Kong tomorrow morning.
-
-
Henlius Entered into a Collaboration with Getz Pharma to Commercialise Adalimumab Biosimilar 汉达远, Covering 11 Emerging Markets in Asia, Africa and Europe
2022-02-23
Shanghai, China, 23rd February, 2022 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Company has entered into a licensing and supply agreement with Getz Pharma (Private) Limited and its affiliated company, Getz Pharma International FZ -LLC (together, “Getz Pharma”), pursuant to which, the company agreed to grant a license to Getz Pharma to commercialise adalimumab biosimilar 汉达远® in Islamic Republic of Pakistan, the Philippines, Vietnam, Cambodia, Myanmar, Nigeria, Kenya, Sri Lanka, Ukraine, Kazakhstan and Uzbekistan, and any other territories to be mutually agreed.